FDA Releases Draft Guidance for Device Investigation of Benign Prostatic Hyperplasia (BPH) Treatment

Summary

The Food and Drug Administration (FDA) has published a draft guidance document outlining updates to the investigation of devices used to treat benign prostatic hyperplasia (BPH), a condition affecting millions of men worldwide, and is seeking feedback from industry and FDA staff before finalizing the guidance.